Drugs@FDA: FDA-Approved Drugs
Abbreviated New Drug Application (ANDA): 215508
Company: HIKMA
Company: HIKMA
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| EDARAVONE | EDARAVONE | 30MG/100ML (0.3MG/ML) | SOLUTION;INTRAVENOUS | Prescription | AP | No | No |
| EDARAVONE | EDARAVONE | 60mg/100mL | INJECTION;SOLUTION | None (Tentative Approval) | None | No | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 05/06/2024 | ORIG-1 | Approval | STANDARD |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/215508Orig1s000ltr.pdf |
EDARAVONE
SOLUTION;INTRAVENOUS; 30MG/100ML (0.3MG/ML)
TE Code = AP
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
|---|---|---|---|---|---|---|---|---|
| EDARAVONE | EDARAVONE | 30MG/100ML (0.3MG/ML) | SOLUTION;INTRAVENOUS | Prescription | No | AP | 216199 | GLAND |
| EDARAVONE | EDARAVONE | 30MG/100ML (0.3MG/ML) | SOLUTION;INTRAVENOUS | Prescription | No | AP | 215508 | HIKMA |
| EDARAVONE | EDARAVONE | 30MG/100ML (0.3MG/ML) | SOLUTION;INTRAVENOUS | Prescription | No | AP | 216902 | SANDOZ |